About Pacira Pharmaceuticals (NASDAQ:PCRX)
Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:PCRX
- CUSIP: 69512710
- Web: www.pacira.com
- Market Cap: $1.33 billion
- Outstanding Shares: 40,341,000
- 50 Day Moving Avg: $36.37
- 200 Day Moving Avg: $42.42
- 52 Week Range: $29.95 - $58.95
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 35.43
- P/E Growth: -3.84
- Annual Revenue: $281.47 million
- Price / Sales: 4.72
- Book Value: $6.47 per share
- Price / Book: 5.09
- EBITDA: ($34,940,000.00)
- Net Margins: -23.36%
- Return on Equity: -12.44%
- Return on Assets: -6.07%
- Debt-to-Equity Ratio: 1.03%
- Current Ratio: 7.84%
- Quick Ratio: 7.26%
- Average Volume: 746,066 shs.
- Beta: 2.12
- Short Ratio: 3.68
Frequently Asked Questions for Pacira Pharmaceuticals (NASDAQ:PCRX)
What is Pacira Pharmaceuticals' stock symbol?
Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."
How were Pacira Pharmaceuticals' earnings last quarter?
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) posted its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.06. The firm earned $70.90 million during the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The business's quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.21 EPS. View Pacira Pharmaceuticals' Earnings History.
When will Pacira Pharmaceuticals make its next earnings announcement?
Where is Pacira Pharmaceuticals' stock going? Where will Pacira Pharmaceuticals' stock price be in 2017?
17 equities research analysts have issued 12-month price objectives for Pacira Pharmaceuticals' stock. Their predictions range from $31.00 to $87.00. On average, they expect Pacira Pharmaceuticals' share price to reach $52.62 in the next year. View Analyst Ratings for Pacira Pharmaceuticals.
What are analysts saying about Pacira Pharmaceuticals stock?
Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Pacira's efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company also remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. Going forwad, Pacira is looking to expand Exparel's label in the animal health market as well. Shares of the company have outperformed the industry year to date. However, Pacira’s dependence on its key marketed drug, Exparel, for top-line growth is concerning. The company also discontinued the production of DepoCyt(e) due to persistent technical issues specific to DepoCyt." (10/9/2017)
- 2. Cowen and Company analysts commented, "Nerve block data for Exparel is anticipated within the next month, and our consultants." (7/14/2017)
- 3. Mizuho analysts commented, "We continue to like PCRX for the 2017 potential catalyst flow (ahead of the nerve block data), growth opportunities from increased DePuy Synthes (DPS) orthopedic promotion, and a reasonable takeout thesis. We updated our share count and interest expense following the recent convertible debt refinancing, and included the latest Feb data from Symphony. While we are comfortable with the growth rates we estimate for the 20 mL vial, we need to monitor our expectations for the smaller 10 mL vial that launched this year and is not yet reported by Symphony. Our estimates came down slightly due to lowered expectations on this 10 mL vial and we lower our PT to $54 from $59 due to additional share count dilution and increase in net debt." (3/23/2017)
Who are some of Pacira Pharmaceuticals' key competitors?
Some companies that are related to Pacira Pharmaceuticals include Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Theravance Biopharma (TBPH), Cambrex Corporation (CBM), Emergent Biosolutions (EBS), Innoviva (INVA), Impax Laboratories (IPXL), Akcea Therapeutics (AKCA), Lannett Co (LCI), Amphastar Pharmaceuticals (AMPH), SciClone Pharmaceuticals (SCLN), AMAG Pharmaceuticals (AMAG), Corium International (CORI), Collegium Pharmaceutical (COLL), Teligent (TLGT), Aceto Corporation (ACET) and Tetraphase Pharmaceuticals (TTPH).
Who are Pacira Pharmaceuticals' key executives?
Pacira Pharmaceuticals' management team includes the folowing people:
- David M. Stack, Chairman of the Board, Chief Executive Officer
- Charles A. Reinhart III, Chief Financial Officer
- Scott N. Braunstein M.D., Senior Vice President - Strategy and Corporate Development
- James B. Jones M.D., Senior Vice President, Chief Medical Officer
- Kristen Marie Williams, Chief Administrative Officer, General Counsel, Secretary
- Robert J. Weiland, Chief Commercial Officer
- Mark Froimson, Director
- Gary Pace Ph.D., Director
- Laura A. Brege, Independent Director
- Yvonne L. Greenstreet M.D., Independent Director
Who owns Pacira Pharmaceuticals stock?
Pacira Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include
HEALTHCOR MANAGEMENT, L.P.
POINT72 ASSET MANAGEMENT, L.P.
(5.10%), Mutual of America Capital Management LLC (0.37%), Nationwide Fund Advisors (0.25%) and Mizuho Securities USA LLC (0.02%). Company insiders that own Pacira Pharmaceuticals stock include David M Stack, James B Jones, James S Scibetta, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.
Who sold Pacira Pharmaceuticals stock? Who is selling Pacira Pharmaceuticals stock?
Pacira Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Mizuho Securities USA LLC. Company insiders that have sold Pacira Pharmaceuticals stock in the last year include David M Stack, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.
Who bought Pacira Pharmaceuticals stock? Who is buying Pacira Pharmaceuticals stock?
Pacira Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC and Nationwide Fund Advisors. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include James B Jones, John P Phd Longenecker, Mark Froimson and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.
How do I buy Pacira Pharmaceuticals stock?
Shares of Pacira Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pacira Pharmaceuticals' stock price today?
MarketBeat Community Rating for Pacira Pharmaceuticals (NASDAQ PCRX)MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Pacira Pharmaceuticals stock can currently be purchased for approximately $32.95.
Consensus Ratings for Pacira Pharmaceuticals (NASDAQ:PCRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||7 Hold Ratings, 10 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.59)|
|Consensus Price Target: ||$52.62 (59.68% upside)|Consensus Price Target History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Analysts' Ratings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/19/2017||Needham & Company LLC||Lower Price Target||Buy -> Buy||$55.00 -> $52.00||N/A|
|10/13/2017||Royal Bank Of Canada||Reiterated Rating||Buy||$54.00||N/A|
|10/4/2017||Bank of America Corporation||Lower Price Target||Buy||$46.00 -> $45.00||Low|
|10/1/2017||Canaccord Genuity||Reiterated Rating||Buy||$48.00 -> $44.00||Low|
|9/28/2017||Goldman Sachs Group, Inc. (The)||Initiated Coverage||Neutral -> Neutral||$41.00||Medium|
|9/7/2017||Jefferies Group LLC||Reiterated Rating||Buy||$59.00||Medium|
|9/7/2017||CIBC||Initiated Coverage||Market Perform -> Market Perform||Low|
|9/7/2017||Oppenheimer Holdings, Inc.||Initiated Coverage||Market Perform||Medium|
|8/21/2017||Janney Montgomery Scott||Upgrade||Sell -> Neutral||$31.00||Low|
|8/3/2017||BMO Capital Markets||Lower Price Target||Market Perform||$42.00 -> $40.00||Low|
|8/3/2017||HC Wainwright||Set Price Target||Buy||$59.00||Medium|
|8/2/2017||Cowen and Company||Reiterated Rating||Hold||Medium|
|3/21/2017||Barclays PLC||Reiterated Rating||Overweight -> Overweight||$54.00 -> $59.00||High|
|3/20/2017||Leerink Swann||Reiterated Rating||Market Perform||High|
|3/14/2017||Piper Jaffray Companies||Reiterated Rating||Overweight||$60.00||Medium|
|10/7/2016||Brean Capital||Initiated Coverage||Hold||N/A|
|1/6/2016||JMP Securities||Reiterated Rating||Mkt Outperform||$92.00||N/A|
Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)Earnings History by Quarter for Pacira Pharmaceuticals (NASDAQ PCRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||Q2 2017||($0.05)||($0.11)||$73.37 million||$70.90 million||View||Listen|
|5/4/2017||Q1 2017||($0.23)||($0.19)||$70.30 million||$69.30 million||View||Listen|
|3/1/2017||Q416||$0.01||$0.09||$73.08 million||$72.90 million||View||Listen|
|11/2/2016||Q316||($0.02)||$0.20||$67.16 million||$68.40 million||View||Listen|
|8/4/2016||Q216||$0.03||$0.19||$67.80 million||$69.60 million||View||Listen|
|5/2/2016||Q116||$0.07||$0.15||$67.11 million||$65.50 million||View||Listen|
|2/25/2016||Q415||$0.27||$0.20||$68.40 million||$69.30 million||View||Listen|
|10/27/2015||Q315||$0.15||$0.10||$60.44 million||$62.20 million||View||Listen|
|7/30/2015||Q215||$0.04||$0.20||$62.97 million||$59.10 million||View||Listen|
|4/30/2015||Q115||$0.02||$0.05||$61.11 million||$58.30 million||View||Listen|
|2/24/2015||Q4||$0.27||$0.35||$61.62 million||$61.80 million||View||Listen|
|10/30/2014||Q314||$0.10||$0.14||$52.20 million||$52.00 million||View||Listen|
|7/31/2014||Q214||($0.21)||$0.04||$42.20 million||$47.20 million||View||Listen|
|5/1/2014||Q1||($0.32)||($0.19)||$35.40 million||$36.70 million||View||Listen|
|10/31/2013||Q313||($0.35)||($0.30)||$22.10 million||$23.30 million||View||Listen|
|11/1/2012||Q312||($0.44)||($0.49)||$7.85 million||$8.50 million||View||N/A|
Earnings Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Insider Ownership Percentage: 6.60%Insider Trades by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/22/2017||Paul J Hastings||Director||Sell||1,044||$36.15||$37,740.60|| |
|8/15/2017||David M Stack||CEO||Sell||28,885||$36.37||$1,050,547.45|| |
|8/15/2017||Kristen Marie Williams||CAO||Sell||3,461||$36.75||$127,191.75|| |
|8/8/2017||Mark Froimson||Director||Buy||100||$37.13||$3,713.00|| |
|6/5/2017||David M Stack||CEO||Sell||4,311||$43.32||$186,752.52|| |
|6/5/2017||James S Scibetta||President||Sell||1,966||$43.32||$85,167.12|| |
|6/5/2017||Kristen Marie Williams||CAO||Sell||1,877||$43.32||$81,311.64|| |
|6/5/2017||Lauren Bullaro Riker||VP||Sell||601||$43.32||$26,035.32|| |
|6/5/2017||Scott Braunstein||SVP||Sell||768||$43.32||$33,269.76|| |
|5/15/2017||James S Scibetta||President||Sell||20,000||$51.20||$1,024,000.00|| |
|5/15/2017||Kristen Marie Williams||CAO||Sell||21,041||$50.86||$1,070,145.26|| |
|1/17/2017||David M. Stack||CEO||Sell||15,000||$38.41||$576,150.00|| |
|1/17/2017||James S Scibetta||President||Sell||20,000||$38.53||$770,600.00|| |
|8/15/2016||David M. Stack||CEO||Sell||15,000||$45.32||$679,800.00|| |
|8/15/2016||James S. Scibetta||President||Sell||25,000||$45.21||$1,130,250.00|| |
|6/7/2016||Lauren Bullaro Riker||VP||Sell||938||$47.66||$44,705.08|| |
|6/6/2016||Kristen Marie Williams||CAO||Sell||600||$47.20||$28,320.00|| |
|6/6/2016||Lauren Bullaro Riker||VP||Sell||321||$47.20||$15,151.20|| |
|6/6/2016||Mark A Kronenfeld||Director||Sell||900||$46.95||$42,255.00|| |
|4/15/2016||David M Stack||CEO||Sell||25,000||$64.14||$1,603,500.00|| |
|1/29/2016||Scott Braunstein||SVP||Buy||2,000||$58.92||$117,840.00|| |
|1/27/2016||James B Jones||SVP||Buy||500||$62.50||$31,250.00|| |
|1/15/2016||David M. Stack||CEO||Sell||15,000||$63.84||$957,600.00|| |
|1/12/2016||James B Jones||SVP||Buy||1,000||$66.00||$66,000.00|| |
|1/12/2016||John P Phd Longenecker||Director||Buy||300||$66.55||$19,965.00|| |
|10/15/2015||David M. Stack||CEO||Sell||15,000||$37.57||$563,550.00|| |
|9/11/2015||James S Scibetta||CFO||Buy||5,000||$61.37||$306,850.00|| |
|8/17/2015||Paul J Hastings||Director||Sell||3,000||$60.02||$180,060.00|| |
|7/15/2015||David M Stack||CEO||Sell||15,000||$67.78||$1,016,700.00|| |
|4/15/2015||David M Stack||CEO||Sell||25,000||$90.50||$2,262,500.00|| |
|4/10/2015||Paul J Hastings||Director||Sell||2,500||$88.00||$220,000.00|| |
|3/16/2015||Lauren Bullaro Riker||Director||Sell||5,000||$95.34||$476,700.00|| |
|3/13/2015||Gary W Pace||Director||Buy||1,000||$93.83||$93,830.00|| |
|2/6/2015||James S Scibetta||CFO||Sell||15,000||$111.22||$1,668,300.00|| |
|1/15/2015||David M Stack||CEO||Sell||15,000||$97.52||$1,462,800.00|| |
|1/12/2015||Paul J Hastings||Director||Sell||2,500||$94.06||$235,150.00|| |
|12/29/2014||John P Phd Longenecker||Director||Sell||1,000||$93.32||$93,320.00|| |
|12/5/2014||Dennis L Winger||Director||Buy||2,645||$94.54||$250,058.30|| |
|11/7/2014||James S Scibetta||CFO||Sell||15,000||$87.18||$1,307,700.00|| |
|11/7/2014||Taunia Markvicka||SVP||Buy||230||$86.62||$19,922.60|| |
|10/10/2014||Paul J Hastings||Director||Sell||2,500||$94.87||$237,175.00|| |
|9/29/2014||John P Phd Longenecker||Director||Sell||1,000||$96.40||$96,400.00|| |
|8/29/2014||Andreas Wicki||Director||Sell||21,494||$108.11||$2,323,716.34|| |
|8/27/2014||Andreas Wicki||Director||Sell||55,813||$108.08||$6,032,269.04|| |
|8/26/2014||Andreas Wicki||Director||Sell||24,207||$108.11||$2,617,018.77|| |
|8/25/2014||Andreas Wicki||Director||Sell||30,000||$108.07||$3,242,100.00|| |
|8/11/2014||Andreas Wicki||Director||Sell||150,000||$101.25||$15,187,500.00|| |
|8/8/2014||James S Scibetta||CFO||Sell||15,000||$99.63||$1,494,450.00|| |
|8/7/2014||Gary Patou||Insider||Sell||20,000||$100.26||$2,005,200.00|| |
|7/15/2014||David M Stack||CEO||Sell||15,000||$86.75||$1,301,250.00|| |
|7/14/2014||Gary Patou||Insider||Sell||29,700||$86.96||$2,582,712.00|| |
|7/10/2014||Paul J Hastings||Director||Sell||2,500||$84.41||$211,025.00|| |
|6/6/2014||Andreas Wicki||Director||Sell||67,900||$82.62||$5,609,898.00|| |
|6/3/2014||Andreas Wicki||Director||Sell||68,000||$80.69||$5,486,920.00|| |
|5/27/2014||Andreas Wicki||Director||Sell||64,400||$77.93||$5,018,692.00|| |
|5/21/2014||Andreas Wicki||Director||Sell||3,600||$77.80||$280,080.00|| |
|5/12/2014||Gary Patou||Insider||Sell||30,000||$74.39||$2,231,700.00|| |
|5/9/2014||David Stack||CEO||Sell||25,000||$73.94||$1,848,500.00|| |
|5/9/2014||Laura Brege||Director||Sell||10,000||$73.85||$738,500.00|| |
|5/8/2014||Andreas Wicki||Director||Sell||23,220||$75.76||$1,759,147.20|| |
|5/8/2014||James Scibetta||CFO||Sell||15,000||$75.05||$1,125,750.00|| |
|5/7/2014||Andreas Wicki||Director||Sell||44,780||$75.78||$3,393,428.40|| |
|3/28/2014||John Phd Longenecker||Director||Sell||1,000||$64.63||$64,630.00|| |
|3/6/2014||Andreas Wicki||Director||Sell||24,887||$80.16||$1,994,941.92|| |
|12/30/2013||David Stack||CEO||Sell||15,000||$55.84||$837,600.00|| |
|12/30/2013||James Scibetta||CFO||Sell||10,000||$55.55||$555,500.00|| |
|12/30/2013||John Phd Longenecker||Director||Sell||2,500||$55.55||$138,875.00|| |
|10/1/2013||Gary Patou||Insider||Sell||20,000||$48.92||$978,400.00|| |
|9/11/2013||Andreas Wicki||Director||Sell||17,783||$37.25||$662,416.75|| |
|8/14/2013||Taunia Markvicka||VP||Sell||14,700||$37.00||$543,900.00|| |
|7/22/2013||Andreas Wicki||Director||Sell||75,958||$35.06||$2,663,087.48|| |
|7/18/2013||Andreas Wicki||Director||Sell||25,560||$33.45||$854,982.00|| |
|7/16/2013||Andreas Wicki||Director||Sell||48,482||$33.28||$1,613,480.96|| |
|7/12/2013||Taunia Markvicka||VP||Sell||29,754||$32.00||$952,128.00|| |
|7/11/2013||Andreas Wicki||Director||Sell||80,000||$31.48||$2,518,400.00|| |
|7/5/2013||Andreas Wicki||Director||Sell||44,021||$30.80||$1,355,846.80|| |
|7/3/2013||Andreas Wicki||Director||Sell||114,448||$30.21||$3,457,474.08|| |
|7/2/2013||Gary Patou||Insider||Sell||40,000||$29.44||$1,177,600.00|| |
|6/28/2013||David M Stack||CEO||Sell||15,000||$28.73||$430,950.00|| |
|6/28/2013||James S Scibetta||CFO||Sell||10,000||$28.05||$280,500.00|| |
|6/28/2013||John P Phd Longenecker||Director||Sell||2,000||$28.09||$56,180.00|| |
|6/24/2013||Fred A Middleton||Director||Sell||75,900||$29.13||$2,210,967.00|| |
|6/20/2013||Fred A Middleton||Director||Sell||144,100||$29.32||$4,225,012.00|| |
|6/19/2013||Andreas Wicki||Director||Sell||35,407||$29.90||$1,058,669.30|| |
|6/17/2013||Andreas Wicki||Director||Sell||50,145||$29.86||$1,497,329.70|| |
|6/13/2013||John Pratt||Insider||Sell||21,032||$30.00||$630,960.00|| |
|6/13/2013||Luke Evnin||Director||Sell||22,746||$30.07||$683,972.22|| |
|6/12/2013||Andreas Wicki||Director||Sell||4,409||$30.00||$132,270.00|| |
|6/11/2013||Andreas Wicki||Director||Sell||11,500||$30.00||$345,000.00|| |
|6/11/2013||John Pratt||Insider||Sell||18,343||$30.00||$550,290.00|| |
|6/5/2013||Andreas Wicki||Director||Sell||15,500||$30.26||$469,030.00|| |
|6/3/2013||Andreas Wicki||Director||Sell||1,900||$30.00||$57,000.00|| |
|5/31/2013||Luke Evnin||Director||Sell||54,517||$30.00||$1,635,510.00|| |
|5/29/2013||Luke Evnin||Director||Sell||215,528||$30.86||$6,651,194.08|| |
|5/22/2013||Andreas Wicki||Director||Sell||18,471||$30.00||$554,130.00|| |
|5/20/2013||Andreas Wicki||Director||Sell||14,374||$30.00||$431,220.00|| |
|3/25/2013||Andreas Wicki||Director||Sell||290,900||$27.95||$8,130,655.00|| |
Headline Trends for Pacira Pharmaceuticals (NASDAQ:PCRX)
Latest Headlines for Pacira Pharmaceuticals (NASDAQ:PCRX)
Loading headlines, please wait.
Pacira Pharmaceuticals (PCRX) Chart for Monday, October, 23, 2017